MedTrace Logo

BF844 Safety and Pharmacokinetic Study in Healthy Volunteers

NCT06592131 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-09-19

No results posted yet for this study

Summary

First-in-Human Phase-1 Clinical Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of BF844 when Administered Orally to Healthy Adult Participants.

Conditions

  • Usher Syndrome Type 3

Interventions

DRUG

BF844

BF844, a small molecule developed by Usheriii Initiative to prevent or delay the progressive hearing and vision loss in patients with Usher syndrome type 3.

Sponsors & Collaborators

  • Usher iii Initiative

    collaborator UNKNOWN

  • EyeXCel Pty. Ltd.

    lead OTHER

Principal Investigators

  • Benedict Tan, MBBS, FRACP · Linear Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-09
Primary Completion
2025-03-06
Completion
2025-09-06

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06592131 on ClinicalTrials.gov